A randomized, double-blind phase I clinical trial of two recombinant dimeric RBD COVID-19 vaccine candidates: Safety, reactogenicity and immunogenicity

BACKGROUND: The Receptor Binding Domain (RBD) of the SARS-CoV-2 spike protein is the target for many COVID-19 vaccines. Here we report results for phase I clinical trial of two COVID-19 vaccine candidates based on recombinant dimeric RBD (d-RBD). METHODS: We performed a randomized, double-blind, pha...

Descripción completa

Detalles Bibliográficos
Autores principales: Pérez-Rodríguez, Sonia, de la Caridad Rodríguez-González, Meiby, Ochoa-Azze, Rolando, Climent-Ruiz, Yanet, Alberto González-Delgado, Carlos, Paredes-Moreno, Beatriz, Valenzuela-Silva, Carmen, Rodríguez-Noda, Laura, Perez-Nicado, Rocmira, González-Mugica, Raúl, Martínez-Pérez, Marisel, Sánchez-Ramírez, Belinda, Hernández-García, Tays, Díaz-Machado, Alina, Tamayo-Rodríguez, Maura, Martín-Trujillo, Alis, Rubino-Moreno, Jorman, Suárez-Batista, Anamary, Dubed-Echevarría, Marta, Teresa Pérez-Guevara, María, Amoroto-Roig, Mayté, Chappi-Estévez, Yanet, Bergado-Báez, Gretchen, Pi-Estopiñán, Franciscary, Chen, Guang-Wu, Valdés-Balbín, Yury, García-Rivera, Dagmar, Verez-Bencomo, Vicente
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Ltd. 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8823954/
https://www.ncbi.nlm.nih.gov/pubmed/35164986
http://dx.doi.org/10.1016/j.vaccine.2022.02.029

Ejemplares similares

Ejemplares similares